| |
Among the most promising immunotherapy approaches are immune checkpoint blockade, adoptive cell therapies, therapeutic vaccines, oncolytic viruses, and mono, bi and trispecific antibodies. Download our white paper to explore advances in cancer immunotherapy and learn how Premier Research can maximize the potential of your program throughout the development lifecycle.
|
|
Today’s Big NewsMay 21, 2024 |
| By James Waldron AstraZeneca’s growing presence in China will play a key role in the Big Pharma’s cell therapy strategy, CEO Pascal Soriot told investors as he set out a bold ambition to almost double global revenues to $80 billion by 2030. |
|
|
|
By Nick Paul Taylor AltruBio has roared back after another pivot in its twisty history, securing up to $225 million in series B funding to take an immune checkpoint enhancer through a midphase ulcerative colitis program. |
By Nick Paul Taylor Eli Lilly is continuing to ride the radiopharma wave, paying Aktis Oncology $60 million upfront to work on therapeutic and diagnostic products against multiple targets. |
By Gabrielle Masson It’s not a double album release, but a close runner-up: The pivotal SWIFT-1 and SWIFT-2 trials have both shown GSK's long-acting asthma treatment reduces attacks. |
|
One major hurdle in therapeutic development is the risk for unwanted immunogenicity, which can lead to decreased efficacy and safety. Gain insight into available tools and de-risk your pipeline - Join your colleagues to discuss on May 22
|
|
By Annalee Armstrong Exscientia is initiating “efficiency measures” to save cash, which will include a workforce reduction of around a quarter of staff while preserving the AI drug hunter’s existing pipeline. |
By Annalee Armstrong Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had remained in part on the program since 2021. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Zoey Becker A newly unsealed complaint from the laboratory that first revealed Zantac's links to a carcinogenic impurity lays out a web of allegations about GSK's efforts to bring the drug to market in the 1980s and its attempts to hide the risks since then. |
By Kevin Dunleavy After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again. On Tuesday morning, AZ unveiled its new plan to swell its revenue to $80 billion by 2030. |
Fierce podcastsDon’t miss an episode |
| | This week’s episode of “The Top Line” is the second part of a three-part series exploring the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
